Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb;6(1):1-8.
doi: 10.5114/ceh.2020.93049. Epub 2020 Feb 17.

How close are we to hepatitis C virus elimination in Central Europe?

Robert Flisiak  1 , Sona Frankova  2 , Ivica Grgurevic  3 , Bela Hunyady  4 , Peter Jarcuska  5 , Limas Kupčinskas  6 , Michael Makara  7 , Marieta Simonova  8 , Jan Sperl  2 , Ieva Tolmane  9 , Adriana Vince  10 , Dorota Zarębska-Michaluk  11
Affiliations

How close are we to hepatitis C virus elimination in Central Europe?

Robert Flisiak et al. Clin Exp Hepatol. 2020 Feb.

Abstract

Aim of the study: To collect and analyse data obtained from HCV opinion leaders/experts from central European countries, on factors which can affect the WHO target of HCV elimination by 2030.

Material and methods: Data were collected from opinion leaders/experts involved in management of HCV infections in Central European countries which participated in 9th Conference of the Central European Hepatologic Collaboration (Warsaw, 10-11 October 2019). A dedicated questionnaire collected current information related to HCV elimination in Bulgaria, Croatia, the Czech Republic, Hungary, Latvia, Lithuania, Poland and Slovakia.

Results: The HCV prevalence rate in particular countries varied from 0.2% to 1.7%. In most central European countries all the HCV infected population is eligible for reimbursement of treatment. However, in some countries there are still some limitations related to the stage of the disease and people who inject drugs. All countries have access to at least one pangenotypic regimen. The most common barrier to HCV elimination in all countries is insufficient political will to establish priority for HCV. None of the reporting countries has established a national screening programme.

Conclusions: Access to therapy for HCV is similar and the majority of patients in Central Europe can be treated according to the current guidelines. Unfortunately there are still some limitations and a lack of political will to implement national screening programmes. According to collected data HCV elimination will not be possible in the region by 2030.

Keywords: epidemiology; hepatitis C virus; liver; therapy.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflict of interest.

References

    1. WHO . Global hepatitis report. Geneva, Switzerland: World Health Organization; 2017. http://apps.who.int/iris/bitstream/10665/255016/1/9789241565455-eng.pdf.
    1. Jančorienė L, Rozentāle B, Tolmane I, et al. Retrospective cross-sectional epidemiologic study on chronic HCV infection in Estonia, Latvia, Lithuania, and Ukraine: virus, patient, and disease characteristics in diagnosed HCV patients under care (RESPOND-C study. Medicina (in press)
    1. Marshall AD, Cunningham EB, Nielsen S, et al. Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. Lancet Gastroenterol Hepatol. 2018;3:125–133. - PubMed
    1. Cooke GS, Andrieux-Meyer I, Applegate TL, et al. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2019;4:135–184. - PubMed
    1. WHO . Global health sector strategy on viral hepatitis 2016-2021. Geneva, Switzerland: World Health Organization; http://apps.who.int/iris/bitstream/10665/246177/1/WHO-HIV-2016.06-eng.pdf.